BooksTestimonialsInterviewsLibraryArticlesShop Here 

Bristol-Myers

The Most Epic Drug Failure. Ever.

By Dr. Mercola

Only a week after the U.S. Centers for Disease Control and Prevention (CDC) advised all U.S. baby boomers to get tested for hepatitis C because it’s suspected that millions may be infected with it, a drug company with a hepatitis C treatment in the pipeline has suddenly abandoned the drug’s trials.

BMS Halts Hep C Drug Work After Patient Dies

Bristol-Myers Squibb announced late Thursday that it's stopping development of an investigational drug for hepatitis C virus (HCV) infection after a patient died of heart failure and eight others were hospitalized.

The drug, an HCV nucleotide polymerase inhibitor called BMS-986094, was being tested in a phase II trial when the case of heart failure was identified. The trial was halted earlier this month.

Bristol-Myers Ends a Hepatitis C Project

Bristol-Myers Squibb said Thursday that it was discontinuing development of a hepatitis C drug that it had acquired in a $2.5 billion deal, after nine patients in a clinical trial had to be hospitalized and one of them died.

The company suspended testing of the drug on Aug. 1, after one patient in a midstage clinical trial experienced heart failure. At that time, however, there was still some question of whether the drug, known as BMS-986094, had caused the problem.

But Thursday evening, the company said that initial patient had died and that eight other patients also had to be hospitalized. Two of them remained hospitalized.

Syndicate content